Debrisoquine metabolism in Chinese patients with Alzheimer's and Parkinson's diseases.
We determined the oxidative phenotype and metabolic ratio of debrisoquine in 96 Chinese patients with Alzheimer's disease (n = 12), Parkinson's disease (n = 55), and using patients with stroke and cervical spondylosis as controls (n = 29). We did not find any difference in debrisoquine metabolic phenotype among Parkinson's disease, Alzheimer's disease, and control patients as judged by chi-square analysis. In addition, the metabolic ratio of all our patients was less than 12.6. The result suggested that Chinese patients with Parkinson's disease and Alzheimer's disease metabolize debrisoquine at a velocity not different from that of their Western counterparts even though the frequency distribution of debrisoquine metabolism phenotyping in these two populations is quite different.
Liu
T Y
TY
Department of Medical Research, Veterans General Hospital-Taipei, Taiwan, ROC.
Chi
C W
CW
Yang
J C
JC
Cheung
S C
SC
Liu
H C
HC
D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism*; D002681:China; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D010300:Parkinson Disease / Q000378:metabolism*; D010641:Phenotype
D003647:Debrisoquin